Radhakrishnan, Adityanarayanan
Friedman, Sam F. https://orcid.org/0000-0002-0688-2169
Khurshid, Shaan
Ng, Kenney https://orcid.org/0000-0003-0792-070X
Batra, Puneet https://orcid.org/0000-0001-6822-0593
Lubitz, Steven A. https://orcid.org/0000-0002-9599-4866
Philippakis, Anthony A. https://orcid.org/0000-0001-6953-3794
Uhler, Caroline https://orcid.org/0000-0002-7008-0216
Funding for this research was provided by:
Eric and Wendy Schmidt Center at the Broad Institute
American Heart Association (18SFRN34250007)
National Science Foundation (DMS-1651995)
United States Department of Defense | United States Navy | Office of Naval Research (N00014-17-1-2147)
Simons Foundation (Simons Investigator Award)
AstraZeneca, MIT-IBM Watson AI Lab
Article History
Received: 20 July 2022
Accepted: 18 April 2023
First Online: 28 April 2023
Competing interests
: S.A.L. receives sponsored research support from Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Fitbit/Google, Medtronic, Premier, and IBM, and has consulted for Bristol Myers Squibb, Pfizer, Blackstone Life Sciences, and Invitae. A.A.P. is a Venture Partner at GV. He has received funding from IBM, Bayer, Pfizer, Microsoft, Verily, and Intel. C.U. serves on the Scientific Advisory Board of Immunai and Relation Therapeutics and has received sponsored research support from Janssen Pharmaceuticals. The remaining authors declare no competing interests.